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Abstract
Background: Overexpression of EGFR is one of the most frequently diagnosed genetic aberrations of glioblastoma
multiforme (GBM). EGFR signaling is involved in diverse cellular functions and is dependent on the type of preferred
receptor complexes. EGFR translocation to mitochondria has been reported recently in different cancer types. However,
mechanistic aspects of EGFR translocation to mitochondria in GBM have not been evaluated to date.
Methodology/Principle Findings: In the present study, we analyzed the expression of EGFR in GBM-patient derived
specimens using immunohistochemistry, reverse-transcription based PCR and Western blotting techniques. In clinical
samples, EGFR co-localizes with FAK in mitochondria. We evaluated this previous observation in standard glioma cell lines
and in vivo mice xenografts. We further analyzed the effect of human umbilical cord blood stem cells (hUCBSC) on the
inhibition of EGFR expression and EGFR signaling in glioma cells and xenografts. Treatment with hUCBSC inhibited the
expression of EGFR and its co-localization with FAK in glioma cells. Also, hUCBSC inhibited the co-localization of activated
forms of EGFR, FAK and c-Src in mitochondria of glioma cells and xenografts. In addition, hUCBSC also inhibited EGFR
signaling proteins in glioma cells both in vitro and in vivo.
Conclusions/Significance: We have shown that hUCBSC treatments inhibit phosphorylation of EGFR, FAK and c-Src forms.
Our findings associate EGFR expression and its localization to mitochondria with specific biological functions in GBM cells
and provide relevant preclinical information that can be used for the development of effective hUCBSC-based therapies.
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Introduction
Epidermal growth factor receptor (EGFR) expression in
glioblastoma multiforme (GBM) has both diagnostic and prog-
nostic significance [1–4]. EGFR signaling plays an important role
in the formation and tumorigenicity of malignant gliomas, and
EGFR overexpression can be found in 40 to 50 percent of patients
with GBM [5]. Multiple histopathological and genetic studies,
together with recent large-scale cancer gene sequencing efforts,
have identified EGFR and its downstream signaling networks as
commonly deregulated components in the primary GBM tumors
[1,6,7]. Furthermore, substantial experimental evidence support a
causal role for aberrant EGFR signaling in cancer pathogenesis
and resistance to treatment [8]. GBM show very high resistance to
treatment with radiation and chemotherapy and aberrant EGFR
signaling contributes to this resistance. Thus, although initial
attempts to target the EGFR have not been effective in GBM [9],
EGFR remains an attractive target for therapeutic intervention in
GBM.
Binding of the ligand epidermal growth factor (EGF) to EGFR
triggers receptor dimerization and activates tyrosine kinase, which
results in phosphorylation of the tyrosine residues of the receptor
and ultimately initiates an array of signaling events [10,11].
Besides the generation of multiple signal transduction events, the
activation of EGFR by ligand also dramatically changes the
cellular localization of receptors by accelerating internalization of
EGFR through clathrin-dependent and -independent endocytic
pathways. EGFR has been found in caveoli, Golgi, endoplasmic
reticulum, lysosome-like structures, nuclear envelopes, nuclei and
within mitochondria [12–14]. EGFR translocates to mitochondria
through interaction with proteins such as cytochrome c oxidase
(Cox) subunit II [12]. Demory et al. [15] hypothesized that EGF
stimulation would lead to EGFR and c-Src activation followed by
translocation of these molecules to the mitochondria, phosphor-
ylation of CoxII by EGFR and/or c-Src, reduction in oxidative
ATP and free radical production, and an increase in cell viability.
However, mechanistic aspects of EGFR translocation to mito-
chondria in GBM have not been evaluated to date. EGFR has
been strongly implicated in the biology of human epithelial
malignancies, with therapeutic applications in cancers of the colon,
head and neck, lung, and pancreas. Accordingly, the targeting of
EGFR has been intensely pursued and has resulted in the
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in clinical oncology and targeted therapy [16]. Suppression of
EGFR expression by siRNA or inhibition of EGFR kinase activity
by an agent, such as gefitinib, has already proved to be of clinical
benefit in the treatment of certain cancer cell types [17–19]. Yao et
al. [20] revealed that mitochondrial location of EGFR was
independent of receptor endocytosis and that gefitinib decreased
cell viability as well as the quantity of mitochondrial EGFR.
Previously, we have shown that treatment of glioma cells with
human umbilical cord blood stem cells (hUCBSC) inhibited the
expression of XIAP, FAK and cyclin D1 with simultaneous
upregulation of PTEN [21–24]. Based on our previous results, we
hypothesized that hUCBSC could efficiently inhibit EGFR
expression as well as its translocation to mitochondria. Hence, in
the present study, we investigated the mitochondrial localization of
EGFR expression in human GBM from several GBM patient–
derived specimens and validated similar phenomenon in standard
glioma cell lines. In addition, we demonstrate that EGFR
translocation to mitochondria and its co-localization with FAK is
highly inhibited after treatment with hUCBSC.
Results
EGFR co-localizes with FAK in clinical samples
Since GBM-patient derived specimens reproduce the genotypic
and phenotypic characteristics of GBM more faithfully than
standard glioma cell lines [25,26], we first examined EGFR status
in GBM-patient derived specimens. Using an immunohistochem-
istry-based strategy, we identified six GBM-patient derived
specimens with high expression of EGFR as compared to normal
brain specimen (Fig. 1A). The mRNA expression levels of EGFR
corresponded to the immunohistochemistry results (Fig. 1B).
However, compared to the expression of EGFR, we did not
observe much expression of FAK in GBM-patient derived
samples. On the contrary, expression of c-Src was higher in
samples where EGFR expression is low (for e.g., hGBM9,
hGBM13) (Fig. 1C). Next, we checked the protein levels of these
molecules. EGFR protein expression levels almost correspond to
the levels observed with immunohistochemistry and mRNA
expression (Fig. 1D). Contrary to this, pEGFR levels can be seen
in only hGBM2 and hGBM6 (Fig. 1E). On the other hand, FAK
expression is seen in all the samples with faint expression in
hGBM8. Higher expression of p-Fak was observed in hGBM6 and
hGBM9 samples with faint expression in remaining clinical
samples. c-Src expression was seen in all GBM samples with faint
expression in hGBM8. Phospho-c-Src expression was observed
only in hGBM2, hGBM3, hGBM9 and hGBM13 samples with
very faint expression in hGBM6. Once we confirmed the presence
of EGFR and FAK in GBM-patient derived samples, we checked
for the co-localization of active forms of FAK and EGFR in
mitochondria. In all clinical samples, co-localization of pEGFR
with pFAK is clearly established in the mitochondria (Fig. 2).
Having confirmed the expression of EGFR in clinical samples and
its association with FAK, we evaluated the significance of
hUCBSC treatment in glioma cells and xenografts in regards to
EGFR status.
hUCBSC treatment inhibits EGFR
Once we confirmed the expression status of EGFR and FAK in
clinical samples, we evaluated the expression levels of EGFR, FAK
and other molecules in human glioma cell lines both in vitro and in
vivo with reference to the treatment effect of hUCBSC in these
glioma cells. Expression of EGFR is highly downregulated in
hUCBSC-treated U87, U251 and 5310 glioma cells as compared
to their controls (Fig. 3A). Similarly, hUCBSC significantly
reduced EGFR expression in U251 and 5310 in vivo xenografts
(Fig. 3B).
Further, we checked the expression of EGFR, FAK and c-Src in
glioma cells lines and their co-cultures with hUCBSC. We
observed that in co-cultures of glioma cells with hUCBSC, the
mRNA levels of EGFR, FAK and c-Src are downregulated
(Fig. 3C, 3D). This is associated with the downregulation of these
molecules at protein levels also (Fig. 3G). We observed that EGFR
and FAK are more significantly downregulated compared to c-Src
(Fig. 3H). To confirm these results, we checked the expression of
these molecules in nude mice brain xenografts. Similar to the in
vitro results, in hUCBSC-treated brain tissues also, mRNAs of
EGFR, FAK and c-Src were downregulated (Figs. 3E, 3F). This
ultimately resulted in the lower expression of these molecules at
protein levels (Figs. 3I, 3J). These results prove that hUCBSC
downregulate EGFR, FAK and c-Src at both transcriptional and
translational stages in both in vitro and in vivo conditions. Since
EGFR plays a vital role in the proliferation of glioma cells, we
tested the expression of Ki67 in U87, U251 and 5310 glioma cells.
These cells express high levels of the ubiquitous proliferation
marker Ki67 (Fig. 4A); treatment with hUCBSC lowered the
expression of Ki67 indicating EGFR-mediated proliferation of
glioma cells is inhibited by hUCBSC treatments. Further, we
checked the co-localization of EGFR and FAK in glioma cells. As
expected pEGFR co-localized with pFAK in glioma cells and this
co-localization was completely inhibited by hUCBSC treatment
(Fig. 4B). To confirm these results, we treated U251, U87 and
5310 cells with external supply of EGF and observed higher
expression of EGFR and FAK as compared to control glioma cells
(Fig. 4C). In another experiment, we treated glioma cells with EGF
initially and then co-cultured these cells with hUCBSC for
72 hours. Even though glioma cells were supplied with exogenous
EGF, hUCBSC were highly efficient in downregulating both
EGFR and FAK in these treatments (Fig. 4D). To further
substantiate these results, we performed cell proliferation assays
based on BrdU incorporation. In all three glioma cell lines of the
present study, hUCBSC inhibited cell proliferation by more than
80% (Fig. 5A). The inhibition of cell proliferation was more
pronounced in hUCBSC-treated 5310 cell lines. In another
experiment, we observed that exogenous supply of EGF increased
cell proliferation of glioma cells by about 10% (Fig. 5B). However,
hUCBSC were able to inhibit proliferation of exogenous EGF-
supplied cells to ,80% than control glioma cells. Further to
compare and evaluate the efficiency of hUCBSC with that of
Temozolomide (TMZ), we performed combination treatments of
hUCBSC and TMZ on glioma cells. TMZ alone inhibited the
proliferation of glioma cells to ,40% (Fig. 5C). However,
combination treatments of hUCBSC and TMZ at different time
intervals showed profound effect on the cell proliferation of glioma
cells compared to single TMZ treatments. These experiments
confirm the efficacy of hUCBSC against EGF-treated glioma cells
and the effect of hUCBSC in inhibiting glioma cell proliferation.
hUCBSC inhibits translocation of phospho-EGFR to
mitochondria of glioma cells
EGFR activation stimulates many complex intracellular signal-
ing pathways. Apart from this activation, EGFR translocates to
mitochondria and co-localizes with FAK to further activate
mitochondria-mediated signaling in glioma cells. Since we
observed that hUCBSC treatments inhibited EGFR expression
in glioma cells, we decided to further evaluate translocation of the
active form of EGFR to mitochondria in glioma cells. In all these
cell lines, translocation of activated EGFR to mitochondria was
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samples also show inhibition of translocation of pEGFR to
mitochondria (Fig. 6B). Thus, under both in vitro and in vivo
conditions, hUCBSC prevented the translocation of pEGFR to
mitochondria. As mentioned earlier, activation of EGFR stimu-
lates activation of many different proteins like FAK and c-Src. We
therefore evaluated the expression of phospho-c-Src in mitochon-
dria of glioma cells. All of the glioma cell lines in the present study
showed higher expression of phospho-c-Src (Fig. 6C). We also
observed higher expression of phospho-c-Src in vivo in nude mice
brain tumors (Fig. 6D). In both cases, the expression of phospho-c-
Src was inhibited by hUCBSC treatments. To confirm these
Figure 1. Expression of EGFR in GBM-patient derived specimens. (A) Control brain and GBM-patient derived specimens were subjected to
DAB immunohistochemistry using anti-rabbit EGFR antibody (bar=200 mm). (B) mRNA extracted from the above specimens was subjected to RT-PCR
using primers specific for EGFR, FAK, c-Src and b-actin (loading control). (C) Quantitative analysis of (B). (D) Tissue lysates (40 mg protein) of the above
specimens were subjected to Western blotting using the following antibodies: EGFR, pEGFR, FAK, pFAK, c-Src and phospho-c-Src. Mouse anti-GAPDH
(1:1000) served as the loading control. (E) Quantitative analysis of (D). *Significant at p,0.05 compared to control brain samples.
doi:10.1371/journal.pone.0031884.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31884Figure 2. Colocalization of pEGFR and pFAK in clinical samples. Control brain and GBM-patient derived specimens were labeled with pEGFR
and pFAK antibodies along with Mito Tracker (green) and processed for immunofluorescence. pEGFR was conjugated with Alexa Fluor 350 (blue) and
pFAK was conjugated with Alexa Fluor 594 (red) secondary antibodies (bar=100 mm).
doi:10.1371/journal.pone.0031884.g002
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31884Figure 3. Inhibition of EGFR by hUCBSC treatment. For in vitro experiments, glioma cells (U251, U87 and 5310) were co-cultured with hUCBSC
for 72 hours. For in vivo experiments, U251 (1610
6 cells) and 5310 (8610
5 cells) tumor cells were intracerebrally injected into the right side of the
brain of the nude mice. Nude mice with pre-established intracranial human glioma tumors (U251 or 5310) were treated with 2610
5 hUCBSC by
intracranial injection. Seven days after tumor implantation, the mice were injected with hUCBSC towards the left side of the brain. Fourteen days after
hUCBSC administration, the brains were harvested, sectioned, and stained with appropriate antibodies. (A) U87, U251 and 5310 glioma cells alone
and after co-culture with hUCBSC were labeled with mouse anti-EGFR antibody and processed for immunofluorescence. EGFR was conjugated with
Alexa Fluor 488 (green) secondary antibody (n=3; bar=100 mm). (B) Control and hUCBSC-treated tumor sections were labeled with mouse anti-EGFR
antibody and processed for DAB immunohistochemistry. For (C) and (E), total mRNA was extracted, converted to cDNA, and subjected to semi-
quantitative RT-PCR. (C) Control and hUCBSC-treated U251, U87 and 5310 in vitro cDNAs were subjected to RT-PCR using EGFR, FAK and c-Src
primers. (D) Quantitative analysis of (C). *Significant at p,0.05 compared to respective control glioma cells. **Significant at p,0.01 compared to
respective control glioma cells. (E) Control and hUCBSC-treated U251 and 5310 in vivo cDNAs were subjected to RT-PCR using EGFR, FAK and c-Src
primers. b-actin served as a loading control. (F) Quantitative analysis of (E). *Significant at p,0.05 compared to respective control glioma tissues. For
(G) and (I), 40 mg of proteins were loaded onto 8% gels and transferred onto nitrocellulose membranes, probed with respective antibodies, and
developed by autoradiography. (G) Control and hUCBSC-treated U251, U87 and 5310 glioma cell lysates were processed and immunoblotted with
EGFR, FAK and c-Src antibodies. (H) Quantitative analysis of (G). **Significant at p,0.01, *Significant at p,0.05 compared to respective control glioma
cells. (I) Control and hUCBSC-treated U251 and 5310 in vivo brain tissue lysates were processed by standard Western blotting and probed with EGFR,
FAK and c-Src antibodies. GAPDH served as a loading control. (J) Quantitative analysis of (I). **Significant at p,0.01, *Significant at p,0.05 compared
to respective control glioma tissue lysates. For (C–J), n$3.
doi:10.1371/journal.pone.0031884.g003
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Src in whole cell lysates and whole tissue lysates of control and
hUCBSC-treated glioma samples. We observed downregulation of
phosphorylated forms of EGFR, FAK and c-Src in hUCBSC-
treated glioma cells (Fig. 7A). Downregulation of active forms of
EGFR and c-Src are more significant compared to FAK in these
cell lysates (Fig. 7B). In a similar fashion, these active forms were
also downregulated in hUCBSC-treated total tissue lysates of brain
xenografts (Figs. 7C, 7D). Compared to total tissue lysates, the
mitochondrial fractions of brain xenografts showed high concen-
tration of phospho-forms of EGFR, FAK and c-Src (Figs. 7E, 7F).
The mitochondrial fractions of U251 control tissues show
68.4960.42% (mean 6 S.D.) of pEGFR whereas 5310 control
tissues show about 53.7262.21% of pEGFR, which means that
out of total pEGFR present in these glioma tissues, major portion
of activated EGFR is translocated to mitochondria (Fig. 7E). The
mitochondrial fractions of hUCBSC treated U251 tissues show
33.2161.52% of pEGFR whereas hUCBSC treated 5310 tissues
show about 24.3960.53% of pEGFR, which means that hUCBSC
inhibited the translocation of pEGFR to mitochondria. Since,
endosomal-lysosomal internalization upon translocation of acti-
vated plasma membrane bound EGFR takes place, we tested this
pathway by immunohistochemistry methods. Probing the control
and hUCBSC-treated nude mice brain sections with Cathepsin-L
antibody, we observed that Cathepsin-L is highly activated in
U251 and 5310 xenograft tumors, and the expression is highly
Figure 4. Inhibition of EGFR and FAK co-localization by hUCBSC. (A) Control and hUCBSC-treated U87, U251 and 5310 glioma cells were
labeled with Ki67 antibody and processed for immunofluorescence. Ki67 was conjugated with Alexa Fluor 594 (red) secondary antibody (n$3;
bar=100 mm). (B) Control and hUCBSC-treated U87, U251 and 5310 glioma cells were labeled with pEGFR and pFAK antibodies and processed for
immunofluorescence. pFAK was conjugated with Alexa Fluor 488 (green) and pEGFR was conjugated with Alexa Fluor 594 (red) secondary antibodies
(n$3; bar=100 mm). (C) Control, EGF-treated, EGF+hUCBSC-treated, and hUCBSC-treated U251, U87 and 5310 cells were processed and 40 mgo f
proteins were loaded onto 8% gels and transferred onto nitrocellulose membranes, probed with EGFR and FAK antibodies, and developed by
autoradiography. GAPDH served as a loading control. n=3. (D) Quantitative analysis of (C). *Significant at p,0.05 compared to respective control
glioma cells by one-way ANOVA.
doi:10.1371/journal.pone.0031884.g004
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31884downregulated in hUCBSC treatments (Fig. S1). These results
confirm that hUCBSC are efficient in inhibiting the phosphory-
lation of EGFR, FAK and c-Src in glioma cells and tissues, thereby
preventing the translocation of EGFR to mitochondria as well as
interaction of EGFR with FAK and c-Src.
Finally, we assessed the expression of EGFR signaling molecules
in glioma cells in vitro and in vivo tumors after treatment with
hUCBSC. The main pathways stimulated by the EGFR are the
mitogen-activated protein kinases (MAPK), the phosphatidylino-
sitol 3-kinase–AKT, and signal transducer and activator of
transcription proteins (STAT), such as STAT3 [27]. In addition,
the activation of STAT3 also relies on the recruitment of the Src
kinase to the EGFR [28,29]. Upon nuclear translocation, the
STAT3 transcription factor up-regulates several genes involved in
cell cycle progression [30,31], cell survival [32] and metastasis
[33]. Another molecule of EGFR signaling cascade RAF1 protein,
can phosphorylate to activate the dual specificity protein kinases
MEK1 and MEK2, which in turn phosphorylate to activate the
serine/threonine specific protein kinases, ERK1 and ERK2.
These key molecules of EGFR signaling MEK1, RAF1, STAT3
and PI3K were downregulated in hUCBSC treated glioma cells
(Fig. 7G). Quantitative analysis shows that both RAF1 and PI3k
(p,0.01) show significant downregulation compared to MEK1
and STAT3 (p,0.05) (Fig. 7H). We also checked the expression of
these molecules in hUCBSC-treated glioma tumors in vivo and
observed that these EGFR signaling molecules are downregulated
compared to untreated tumors (Fig. 7I). Similar to our in vitro
results, RAF1 and PI3k (p,0.01) molecules show significant
downregulation compared to MEK1 and STAT3 (p,0.05) by
hUCBSC treatments (Fig. 7J). Finally, we observed tumor size
regression by about 75% in hUCBSC-treated in vivo nude mice
brains of both U251 and 5310 xenografts (Fig. 7K). Our results
show that hUCBSC has the ability to downregulate the expression
of multiple members of EGFR signaling cascades, in both in vitro
and in vivo conditions.
Discussion
Overexpression of EGFR is one of the most frequently
diagnosed genetic aberrations of glioblastoma multiforme
(GBM). EGFR signaling is involved in diverse cellular functions
and is dependent on the type of preferred receptor complexes.
EGFR activation stimulates many complex intracellular signaling
pathways that are tightly regulated by the presence and identity of
the ligand, heterodimer composition, and the availability of
phosphotyrosine-binding proteins. The two primary signaling
pathways activated by EGFR include the RAS/RAF/MEK/ERK
and the PI3K/AKT axes; however, Src tyrosine kinases, PlCc,
PKC, and STAT activation and downstream signaling have also
been well documented [16,34,35]. EGFR gene amplification is
one of the most common genetic changes in GBM and can lead to
the activation of various downstream signaling molecules,
including STAT3, MAPK, and AKT [36]. Receptor phosphor-
ylation leads to the recruitment of multiple effector proteins
through recognition and binding of Src homology 2 (SH2) and
phosphotyrosine binding (PTB) domains on the effector proteins to
phosphotyrosine motifs on the receptor [37]. The formation of this
signaling complex results in the initiation of various downstream
signaling cascades, including the phosphoinositide-3-kinase
(PI3K), mitogen-activated protein kinase (MAPK), and signal
transducer and activator of transcription 3 (STAT3) pathways,
which regulate a multitude of cellular responses. To evaluate the
signaling pathways mediated by EGFR, we determined the
expression of EGFR in GBM-patient derived specimens. Our
results confirm that immunohistochemically detectable EGFR is
overexpressed in some grade IV glioblastoma samples. These
results are in correlation with transcriptional and translational
status of EGFR expression. However, in regards to the clinical
outcome, EGFR expression did not correlate with other molecules
like FAK. EGFR staining was negative in the normal brain
samples and these results suggest that EGFR expression is an
indicator of a malignant phenotype of the majority of GBM. Co-
overexpression of EGFR, FAK and c-Src frequently occurs in
human tumors and is linked to enhanced tumor growth [38,39]. In
the present study, we also observed co-localization of EGFR with
FAK in mitochondria of GBM-patient derived specimens, which is
indicative of the roles of EGFR, FAK and mitochondria in
enhanced tumor growth.
In recent years, EGFR has become a promising target for
therapies for different tumors. The poor prognosis of GBM
patients is due in part to classical chemo- and radioresistance
properties demonstrated by these tumors. Newly diagnosed GBM
patients typically undergo surgical resection of the tumor followed
by concomitant temozolamide (TMZ) treatment and radiotherapy
and subsequent administration of TMZ for 6 months as adjuvant
chemotherapy [40]. Because EGFRvIII has been shown to
contribute to tumor progression and chemo-radioresistance, an
attractive strategy would be to develop targeted therapeutics
against this receptor for use as a monotherapy, thereby minimizing
the systemic side effects of whole-brain irradiation and TMZ
administration, especially because genetic manipulation of
EGFRvIII has resulted in tumor shrinkage in a preclinical setting
[8]. The monoclonal anti-EGFR antibody cetuximab and the
EGFR tyrosine kinase inhibitor erlotinib led (in monotherapy or in
combination with cytotoxic drugs) to improved survival in patients
with colorectal cancer, non-small cell lung cancer and advanced
pancreatic cancer [41–43]. Based on these earlier reports and our
successful results with GBM tumor regression by hUCBSC, we
hypothesized that hUCBSC could efficiently downregulate the
expression of EGFR and its signaling molecules. Previously, we
reported that hUCBSC inhibit FAK expression and its related
angiogenesis in GBM in vitro and in vivo [22]. In the present study,
we observed downregulation of EGFR expression in glioma cells.
Even when we supplied exogenous EGF, which increases EGFR
expression of glioma cells in a drastic manner, treatment with
hUCBSC efficiently inhibited the expression of both EGFR and
FAK in these cells.
Although generally represented as a plasma membrane protein,
EGFR has been found in the nucleus and sub-cellular organelles.
Recently, the mitochondrial localization of the EGFR was
Figure 5. Inhibition of cell proliferation by hUCBSC treatments. (A) Control and hUCBSC-treated glioma cells at different time points were
analyzed for cell proliferation by incorporation of BrdU. *Significant at p,0.05 compared to respective control cells. **Significant at p,0.01 compared
to respective control cells (by t-test). (B) Control, EGF-treated and EGF+hUCBSC treated glioma cells were analyzed for cell proliferation. *Significant at
p,0.05 both for control vs. EGF+hUCBSC treatment and EGF vs. EGF+hUCBSC treatments (one-way ANOVA followed by Bonferroni’s post hoc test).
(C) Control, TMZ treated, TMZ+hUCBSC treated glioma cells were subjected to cell proliferation analysis by BrdU incorporation. *Significant at p,0.05;
**Significant at p,0.01 both for control vs. TMZ treatment and control vs. TMZ+hUCBSC treatments (one-way ANOVA followed by Bonferroni’s post
hoc test). For all these tests, raw data was taken into consideration to perform statistical analyses and then results were presented as % control values.
Each bar represents n$6.
doi:10.1371/journal.pone.0031884.g005
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metabolic processes including proliferation, programmed cell
death execution and signal transduction [44–46]. Recent reports
reveal that there exists an integrated signal system in the
mitochondrion to coordinate the various molecular messages that
enter and exit the mitochondrion according to the diverse needs of
Figure 6. Downregulation of pEGFR and phospho-c-Src in mitochondria in hUCBSC treatments. (A) Control and hUCBSC-treated U251,
U87 and 5310 cells were labeled with pEGFR and Mito Tracker green and processed for immunofluorescence. (B) Control and hUCBSC-treated U251
and 5310 tissue sections were labeled with pEGFR and Mito Tracker green and processed for immunofluorescence. pEGFR was conjugated with Alexa
Fluor 594 (red) secondary antibody (n$3; bar=100 mm). (C) Control and hUCBSC-treated U251, U87 and 5310 cells were labeled with phospho-c-Src
and Mito Tracker green and processed for immunofluorescence. (D) Control and hUCBSC-treated U251 and 5310 tissue sections were labeled with
phospho-c-Src and Mito Tracker green and processed for immunofluorescence. Phospho-c-Src was conjugated with Alexa Fluor 594 (red) secondary
antibody (n$3; bar=100 mm).
doi:10.1371/journal.pone.0031884.g006
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31884Figure 7. Downregulation of EGFR-mediated signaling molecules in hUCBSC treatments. For (A), (C), (E), (G) and (I) 40 mg of proteins were
loaded onto 8–12% gels and transferred onto nitrocellulose membranes, probed with respective antibodies, and developed by autoradiography. (A) In
vitro samples probed with pEGFR, pFAK, p-c-Src and GAPDH. (B) Quantitative analysis of (A). *Significant at p,0.05 compared to respective control
glioma cells. (C) In vivo cytosolic fractions probed with pEGFR, pFAK, p-c-Src and GAPDH. n=3. (D) Quantitative analysis of (C). *Significant at p,0.05
compared to respective control glioma tissues. (E) In vivo mitochondrial fractions probed with pEGFR, pFAK, p-c-Src and Cox IV. n=3. (F) Quantitative
analysisof (E). *Significantatp,0.05 comparedto respective controlgliomatissues. Control andhUCBSC-treated U251,U87and5310 gliomacell lysates
(G)andcontrol andhUCBSC-treated U251 and5310 gliomatissuelysates (I)were processed forimmunoblottingandprobedwith MEK1,RAF1,Stat3 and
PI3K antibodies. GAPDH served as a loading control. (H) Quantitative estimation of (G). *Significant at p,0.05 compared to respective glioma control
cells.**Significantatp,0.01comparedtorespectivegliomacontrolcells.(J)Quantitativeestimationof(I).*Significantatp,0.05comparedtorespective
glioma control tissues. **Significant at p,0.01 compared to respective glioma control tissues. (K) Tumor size volume estimated in control and hUCBSC
treated nude mice brains. *Significant at p,0.05 compared to glioma controls. Error bars indicate 6 SD. For (A) to (K), n$3.
doi:10.1371/journal.pone.0031884.g007
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transcriptional factors, which are not conventionally mitochondri-
al resident members, are revealed to have a mitochondrial location
[44,48]. However, the molecular mechanisms underlying EGFR
localization in mitochondria remain largely unknown. EGFR
mitochondrial localization is regulated by either autophagy or
programmed cell death and is correlated with cell survival [50].
Demory et al. [15] postulated that EGF stimulation would lead to
EGFR and c-Src activation followed by translocation of these
molecules to the mitochondria, phosphorylation of CoxII by
EGFR and/or c-Src, reduction in oxidative ATP and free radical
production, and an increase in cell viability. Mitochondrial-
localized EGFR is independent of its internalization and may be
correlated with cell survival and participate in the ligand-induced
programmed cell death [20]. In our studies, we observed that
phosphorylation of EGFR is inhibited by hUCBSC treatments.
Unless EGFR is activated, it cannot translocate to mitochondria or
any other sub-cellular organelles. Hence, we could not observe
translocation of EGFR to mitochondria in hUCBSC-treated in
vitro and in vivo samples. Further, we did not observe any co-
localization of activated EGFR and FAK molecules in mitochon-
dria after hUCBSC treatments.
In summary, our data indicate that hUCBSC coordinately
regulates EGFR signaling at cytosolic and mitochondrial levels in
glioma cells. The effect of hUCBSC action is to inhibit cell cycle
progression and reduce cell growth and viability as reported
previously. The reported down-regulation of EGFR in GBM
tumors, together with the ability to regulate oncogenic EGFR
signaling in glioma cell lines, suggests the therapeutic potential of
hUCBSC in regulating GBM tumors. The inhibition of EGFR by
hUCBSC can be effective in the treatment of GBM. Our previous
findings indicated that hUCBSC can inhibit cell viability by
initially reducing the content of mitochondrial membrane
potential [21]. The results of the present study show that
inhibition of EGFR localization to mitochondria provide further
evidence of the growth inhibitory effect of hUCBSC on glioma
cells. Our findings show that hUCBSC inhibit EGFR localization
in mitochondria in GBM cells and provide relevant preclinical
information that can be exploited for the development of effective
hUCBSC-based therapies.
Materials and Methods
Ethics Statement
After obtaining informed consent, human umbilical cord blood
was collected from healthy volunteers according to a protocol
approved by the Peoria Institutional Review Board, Peoria, IL,
USA. The consent was written and approved. The approved
protocol number is 06-014, dated December 10, 2009 and
renewed on November 11, 2010. The Institutional Animal Care
and Use Committee of the University Of Illinois College Of
Medicine at Peoria, Peoria, IL, USA approved all surgical
interventions and post-operative animal care. The consent was
written and approved. The approved protocol number is 851,
dated November 20, 2009 and renewed on March 15, 2011.
Cell cultures
Two high-grade human glioma cell lines (U251, U87) and one
xenograft cell line (5310) were used for this study. U251 and U87
cells were obtained from American Type Culture Collection
(ATCC, Manassas, VA). The 5310 xenograft cell line was kindly
provided by Dr. David James at University of California, San
Francisco. U251 and U87 cells were grown in DMEM
supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, UT) and 1% penicillin-streptomycin (Invitrogen, Carlsbad,
CA). The 5310 xenograft cell line was grown in RPMI 1640
medium supplemented with 10% FBS and 1% penicillin-
streptomycin. For hUCBSC, after obtaining informed consent,
human umbilical cord blood was collected from healthy volunteers
according to a protocol approved by the University Of Illinois
College Of Medicine at Peoria Institutional Review Board. Cord
blood was processed as described previously by sequential Ficoll
density gradient purification [51]. Next, we selected cells using
CD29
+ and CD81
+ markers as described previously. The
nucleated cells were grown in mesencult medium (Stem Cell
Technologies, Vancouver, Canada) supplemented with 20% FBS
and 1% penicillin-streptomycin and plated in 100-mm culture
dishes. All the cells were grown at 37uC in an incubator with a 5%
CO2 atmosphere. For co-culture experiments, hUCBSC and
glioma cells were cultured at a ratio of 1:1 (1610
6 for each cell
line) for 72 hours. Co-cultures of hUCBSC and U251, hUCBSC
and U87 were grown in DMEM (with 10% FBS) and co-cultures
of hUCBSC and 5310 were grown in RPMI-1640 (with 10% FBS)
and then FACS sorted as described previously [24].
Collection of patients’ specimens
GBM specimens were collected from patients with histologic
diagnosis of primary GBM (WHO grade IV astrocytoma) in
accordance with the protocol approved by the University Of
Illinois College Of Medicine at Peoria Institutional Review Board.
Tumor diagnosis and grading were blind-reviewed by a neuropa-
thologist. Samples that did not satisfy the inclusion criteria of
primary GBM (e.g., GBM with oligodendroglioma features) were
excluded from the study.
BrdU assay for cell proliferation
Cell proliferation analysis was performed using Cell Prolifera-
tion ELISA (colorimetric) BrdU incorporation assay (Roche
diagnostics, Indianapolis, IN) according to the manufacturer’s
protocol. Cells (0.5610
4 cells/well) were cultured in 96-well plates
for different time periods (48 h, 72 h and 96 h for coculture
treatments with hUCBSC) and treatments and incubated for
12 hours with BrdU reagent. An anti-BrdU antibody was added,
and the immune complexes were detected by subsequent substrate
reaction. The reaction product was quantified as per manufac-
turer’s instructions.
EGF and TMZ treatments
Glioma cells were subjected to serum starvation for 3 hours and
then treated with EGF (100 ng/mL) for 1 hour in serum free
medium. After EGF treatment, the cells were washed twice with
PBS and harvested. In another experiment, glioma cells that were
given EGF treatment were co-cultured with hUCBSC in 1:1 ratio
for 72 hours as described above. For Temozolomide (TMZ)
treatments, the glioma cells were subjected to serum starvation for
3 hours and then treated with TMZ (1000 mM) for 24 h in serum
free medium. In combination treatments with hUCBSC, stem cell
treatments were given at different time periods (48 h, 72 h and
96 h) either before or after treatment with TMZ. In both EGF and
TMZ treatments, we tested different concentrations and time
periods and finally selected the above time points and concentra-
tions which yield optimum results (data not shown).
RNA analysis
Total RNA from GBM patient-derived tumor specimens
(frozen) and from control and hUCBSC-treated glioma cell lines
was extracted using the RNeasy Mini Kits (Qiagen, Valencia, CA).
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synthesis kit (Roche, Indianapolis, IN) by reverse transcription-
based PCR (RT-PCR). All cDNAs were normalized to the b-actin
RT-PCR product. PCR amplification was performed using the
primer sets listed below, amplified by 35 cycles of PCR (94uC,
1 min; 60uC, 1 min; 72uC, 1 min) using 20 pM of specific
primers.
Primers used for RT-PCR
EGFR Forward 59ccaagggagtttgtggagaa39
Reverse 59cttccagaccagggtgttgt39
FAK Forward 59ggtgcaatggagcgagtatt39
Reverse 59gccagtgaacctcctctga39
c-Src Forward 59gggtagcaacaagagcaa39
Reverse 59gagttgaagcctccgaacag39
b-Actin Forward 59ggcatcctcaccctgaagta39
Reverse 59ggggtgttgaaggtctcaaa39
Immunoblot analysis
Single and co-cultures of glioma cells or nude mice brain tissues
(frozen) were harvested and homogenized in four volumes of
homogenization buffer as described previously [51]. Samples (40–
50 mg of total protein/well) were subjected to 8–12% SDS-PAGE
and transferred onto nitrocellulose membranes. The reaction was
detected using Hyperfilm-MP autoradiography film (Amersham,
Piscataway, NJ). The following antibodies were used for Western
blot analysis: mouse anti-EGFR (1:500), goat anti-pEGFR (1:500),
mouse anti-FAK (1:500), goat anti-phospho-FAK (1:500), mouse
anti-c-Src (1:500), mouse anti-MEK1 (1:500), rabbit anti-RAF1
(1:500), mouse anti-STAT3 (1:500), mouse anti-PI3K (1:500) (all
from Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit anti-
phospho-c-Src (1:1000; Cell Signaling). Immunoreactive bands
were visualized using chemiluminescence ECL Western blotting
detection reagents (Amersham). Immunoblots were stripped and
redeveloped with GAPDH antibody [mouse anti-GAPDH
(1:1000; Santa Cruz)] to ensure equal loading levels. Experiments
were performed in triplicate. The bands in each blot were
quantified using ImageJ software and the values were expressed in
relation of GAPDH values.
Intracranial tumor growth inhibition
The Institutional Animal Care and Use Committee of the
University Of Illinois College Of Medicine at Peoria approved all
surgical interventions and post-operative animal care. For the
intracerebral tumor model, U251 (1610
6 cells) and 5310 (8610
5
cells) tumor cells were intracerebrally injected into the right side of
the brain of the nude mice as described previously [23]. Seven
days after tumor implantation, the mice were injected with
hUCBSC in the contralateral left brain hemisphere. The ratio of
the hUCBSC to cancer cells was maintained at 1:4. Three weeks
after tumor inoculation, six mice from each group were sacrificed
by cardiac perfusion with 4% formaldehyde in PBS, their brains
were removed, and paraffin sections were prepared. Sections were
stained with H&E to visualize tumor cells and to examine tumor
volume. The sections were blindly reviewed and scored semi-
quantitatively for tumor size. Whole-mount images of brains were
also taken to determine infiltrative tumor morphology. The
average tumor area per section integrated to the number of
sections where the tumor was visible was used to calculate tumor
volume and compared between controls and treated groups.
Immunoblot analyses and RT-PCR were carried out on fresh
brain tissues.
Immunostaining analyses
GBM patient-derived specimens and brains of control and
hUCBSC-treated mice were fixed in formaldehyde and embed-
ded in paraffin as per standard protocols. Sections were
deparaffinized and blocked in 1% BSA in PBS for 1 hour, and
the sections were subsequently transferred to primary antibody
diluted in either 1% BSA (for pEGFR and pFAK antibodies) or
10% normal goat serum (1:100) (for all other antibodies). Sections
were allowed to incubate in the primary antibody solution
overnight at 4uC in a humidified chamber. Sections were then
washed in PBS and placed in either 1% BSA or 10% goat serum
with the appropriate secondary antibody. The sections were
incubated with the secondary antibody for 1 hour and visualized
using a confocal microscope. Transmitted light images were
obtained after H&E staining as per standard protocol to visualize
the morphology of the sections. Negative controls were
maintained without primary antibody or by using IgG fraction.
For DAB immunohistochemistry, sections were probed with
antibodies and then stained with DAB (Sigma) and further
stained with Hematoxylin. For immunofluorescence studies,
cultured glioma cells plated in 2-well chamber slides were rinsed
twice with phosphate buffered saline (PBS) and fixed in 4%
paraformaldehyde. After additional PBS rinses, cells were blocked
with 16 PBS with 1% bovine serum albumin (BSA) for 1 hour.
Primary antibodies (1:100 dilutions) were diluted in either 10%
goat serum or 1% BSA and applied overnight at 4uC. Alexa
Fluor-conjugated secondary antibodies were diluted (1:200) in
either 10% goat serum or 1% BSA and applied individually for
1 hour at room temperature. We used the following antibodies:
mouse anti-EGFR, mouse anti-Ki67, rabbit anti-FAK, goat anti-
pEGFR, mouse anti-phospho-c-Src (all from Santa Cruz
Biotechnology). For mitochondrial localization, we used Mito
Tracker Green (Invitrogen) as per the manufacturer’s instruc-
tions. Before mounting, the cells were stained with 49,6 -
diamidino-2-phenylindole (DAPI). The cells were observed using
a fluorescence microscope (Olympus IX71, Olympus, Melville,
NY) and/or a confocal microscope (Olympus Fluoview) and
photographed. We used same antibodies for both immunofluo-
rescence studies and immunohistochemistry studies. Negative
controls were maintained without primary antibody or by using
IgG fraction.
Statistical analyses
Values are shown as mean 6 SD of at least three independent
experiments. Results were analyzed using a two-tailed Student’s t-
test using Graph Pad Prism version 3.02, a statistical software
package. Results were considered statistically significant at p,0.05
or p,0.01. For comparing more than two groups, statistical
significance using one way analysis of variance (ANOVA) was
used. Data for each treatment group were represented as mean 6
SEM and compared with other groups for significance by one-way
ANOVA followed by Bonferroni’s post hoc test (multiple
comparison tests) using Graph Pad Prism version 3.02. Results
were considered statistically significant at a p,0.05 or p,0.01.
Supporting Information
Figure S1 Inhibition of lysosomal internalization by
hUCBSC treatments. Control and hUCBSC-treated nude
mice brain sections were immunoprobed with mouse anti-
Cathepsin L antibody and processed for DAB staining followed
by Hematoxylin staining. Bar=200 mm. n$3.
(TIF)
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